Mirae Asset Global Investments Co. Ltd. Has $16.37 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 8.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 181,313 shares of the medical equipment provider’s stock after purchasing an additional 14,586 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Boston Scientific were worth $16,372,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BSX. Global Wealth Strategies & Associates lifted its holdings in Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $29,000. Dunhill Financial LLC lifted its position in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 152 shares during the last quarter. Values First Advisors Inc. bought a new stake in Boston Scientific during the 3rd quarter valued at approximately $28,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new position in Boston Scientific in the 3rd quarter worth approximately $30,000. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,302 shares of company stock valued at $4,464,725 over the last 90 days. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. Mizuho raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Piper Sandler boosted their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday. Raymond James raised their price objective on Boston Scientific from $101.00 to $119.00 and gave the stock a “strong-buy” rating in a research report on Friday, January 31st. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Finally, Canaccord Genuity Group raised their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $100.39.

Boston Scientific Trading Up 1.4 %

Shares of BSX opened at $104.95 on Thursday. The firm has a market capitalization of $154.68 billion, a PE ratio of 86.73, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $64.08 and a 12-month high of $107.17. The stock’s fifty day simple moving average is $94.01 and its 200-day simple moving average is $86.71.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. As a group, research analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.